Report on Cancer Immunotherapy Market & Clinical Pipeline Insight

Reporter: Aviva Lev-Ari, PhD, RN

 

SOURCE

http://www.kuickresearch.com/press-details.php?presstitle=Immunotherapy-To-Transform-Cancer-Drug-Market-Dynamics

 

Release Date: 6-Aug-2014

Currently there are 605 Cancer Monoclonal Antibodies, 289 Cancer Vaccines, 40 Oncolytic Viruses Drugs, 64 Cytokines Therapies & 82 Cell Therapies are in Clinical Pipeline “Cancer Immunotherapy Market & Clinical Pipeline Insight” Report Highlights: Cancer Immunotherapy Market Overview Cancer Immunotherapy Market Dynamics Cancer Immunotherapy Pipeline: 1080 Drug in Clinical Pipeline Cancer Monoclonal Antibodies Clinical Pipeline by Phase & Country Cancer Vaccine Clinical Pipeline by Phase & Country Oncolytic Viruses Clinical Pipeline by Phase & Country Cancer Cytokine Therapy Clinical Trial Insight by Phase & Country Cancer Cell Therapy Clinical Trial Insight by Phase & Country Currently there are 605 Cancer Monoclonal Antibodies, 289 Cancer Vaccines, 40 Oncolytic Viruses Drugs, 64 Cytokines Therapies & 82 Cell Therapies are in Clinical Pipeline   The recent years have witnessed the emergence of cancer immunotherapy, which has the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past 15 years, the researchers have increased their learning about the human body’s immune system, which has led to the achievement of significant number of regulatory milestones during this period. Cancer immunotherapy has been made commercial and the market availability of the agents has enabled the pharma companies to develop novel combination approaches which have the capability to provide even greater insight into the body’s immune system. With the introduction of Yervoy as one of the agents of cancer immunotherapy, it has been identified that there is a large window of opportunity for treating cancer patients successfully. It has been observed that with the use of Yervoy, in the long-term, a majority of the patients have remained free of relapse of cancer for many years. Thus, this finding has strengthened the understanding that the field of cancer immunotherapy has a disruptive potential in the future years after its complete development. For Report Sample Visit: Cancer Immunotherapy Market & Clinical Pipeline Insight Or Contact: avinash@kuickresearch.com

 

 

 

Cancer Immunotherapy Market & Clinical Pipeline Insight

Publish Date:- Jul-2014       No Of Pages (1990)                                              Electronic Access – Single User License $3000 Buy Now                                              CD-ROM Mail Delivery $3600 Buy Now                                              Hard Copy Mail Delivery $4200 Buy Now                                              Electronic Access – Multi-User License $6000 Buy Now 1. Introduction to Cancer Immunotherapy (Page 6)   2. Mechanism of Cancer Immunotherapy (Page 11) 2.1 Genetic engineering 2.2 Hybridoma Technology 2.3 Humanization of Monoclonal Antibodies 2.4 Overcoming the HAMA Response via Modern Technology   3. Types of Cancer Immunotherapy (Page 14) 3.1 Monoclonal Antibodies 3.2 Checkpoint Inhibitors 3.3 Vaccination 3.4 Non Specific Immunotherapies   4. Why Need for Cancer Immunotherapy (Page 23)   5. Global Cancer Immunotherapy Market Overview (Page 26)   6. Cancer Immunotherapy Market Dynamics (Page 33) 6.1 Favorable Market Drivers 6.2 Key issues to be Discussed 6.3 Future of Cancer Immunotherapy   7. Cancer Monoclonal Antibodies Clinical Pipeline by Phase & Country (Page 41) 7.1 Clinical Pipeline Overview 7.2 Clinical Pipeline Insight: Research till Registration 7.3 Marketed Cancer Monoclonal Antibodies   8. Cancer Vaccine Clinical Pipeline by Phase & Country (Page 1088) 8.1 Clinical Pipeline Overview 8.2 Clinical Pipeline Insight: Research till Registration 8.3 Marketed Cancer Vaccines   9. Oncolytic Viruses Clinical Pipeline by Phase & Country (Page 1640) 9.1 Clinical Pipeline Overview 9.2 Clinical Pipeline insight: Research till Registration   10. Cancer Cytokine Therapy Clinical Trial Insight by Phase & Country (Page 1714) 10.1 Clinical Pipeline Overview 10.2 Clinical Pipeline Insight: Research till Preregistration 10.3 Marketed Cancer Cytokines Threapy   11. Cancer Cell Therapy Clinical Trial Insight by Phase & Country (Page 1844) 11.1 Clinical Pipeline Overview 11.2 Clinical Pipeline Insight: Research till Preregistration 11.3 Marketed Cancer Cell Therapy   12. Competitive Landscape: Business Overview & Product Pipeline (Page 1977) 12.1 Advaxis 12.2 Celldex Therapeutics 12.3 Dendreon Corporation 12.4 Galena Biopharma 12.5 ImmunoCellular Therapeutics 12.6 ImmunoGen 12.7 Inovio Pharmaceuticals 12.8 Merck 12.9 NeoStem Oncology 12.10 NewLink Genetics 12.11 Northwest Biotherapeutics 12.12 Novartis 12.13 Peregrine Pharmaceuticals 12.14 Roche 12.15 Seattle Genetics

 

Share this:

• Click to share on Twitter (Opens in new window)
• Click to share on LinkedIn (Opens in new window)
• Click to share on Facebook (Opens in new window)
• Click to print (Opens in new window)
• Click to email this to a friend (Opens in new window)

Like this:

Like Loading...

Posted in CANCER BIOLOGY & Innovations in Cancer Therapy, Human Immune System in Health and in Disease | 1 Comment

One Response

1. on August 31, 2020 at 8:40 AM | Reply Steroids, Inflammation, and CAR-T Therapy | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

   This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.

   A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.

   Loading...